Clinical Presentation and Treatment of High-Risk Sarcoidosis

被引:12
|
作者
Perlman, David M. [1 ]
Sudheendra, Muthya Tejasvini [1 ]
Furuya, Yuka [1 ]
Shenoy, Chetan [2 ]
Kalra, Rajat [2 ]
Roukoz, Henri [2 ]
Markowitz, Jeremy [2 ]
Maier, Lisa A. [3 ]
Bhargava, Maneesh [1 ]
机构
[1] Univ Minnesota, Dept Med, Sch Med, Div Pulm Allergy Crit Care & Sleep Med, Minneapolis, MN 55455 USA
[2] Univ Minnesota, Dept Med, Sch Med, Div Cardiovasc, Minneapolis, MN 55455 USA
[3] Natl Jewish Hlth, Div Environm & Occupat Hlth Sci, Denver, CO USA
关键词
high-risk sarcoidosis; cardiac sarcoidosis; progressive pulmonary sarcoidosis; neurosarcoidosis; multiorgan sarcoidosis; POSITRON-EMISSION-TOMOGRAPHY; LONG-TERM OUTCOMES; 6-MINUTE WALK TEST; PULMONARY SARCOIDOSIS; CARDIAC SARCOIDOSIS; CORTICOSTEROID-THERAPY; VENTRICULAR-ARRHYTHMIAS; MAGNETIC-RESONANCE; CNS SARCOIDOSIS; HYPERTENSION;
D O I
10.1513/AnnalsATS.202102-212CME
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Sarcoidosis is a multisystem disease of unknown cause with heterogeneous clinical manifestations and variable course. Spontaneous remissions occur in some patients, whereas others have progressive disease impacting survival, organ function, and quality of life. Four high-risk sarcoidosis phenotypes associated with chronic inflammation have recently been identified as highpriority areas for research. These include treatment-refractory pulmonary disease, cardiac sarcoidosis, neurosarcoidosis, and multiorgan sarcoidosis. Significant gaps currently exist in the understanding of these high-risk manifestations of sarcoidosis, including their natural history, diagnostic criteria, biomarkers, and the treatment strategy, such as the ideal agent, optimal dose, and treatment duration. The use of registries with well-phenotyped patients is a critical first step to study high-risk sarcoidosis manifestations systematically. We review the diagnostic and treatment approach to high-risk sarcoidosis manifestations. Appropriately identifying these disease subgroups will help enroll well-phenotyped patients in sarcoidosis registries and clinical trials, a necessary step to narrow existing gaps in understanding of this enigmatic disease.
引用
收藏
页码:1935 / 1947
页数:13
相关论文
共 50 条
  • [41] Treatment regimens in high-risk CLL
    Huber, H.
    Tausch, E.
    Schneider, C.
    Edenhofer, S.
    von Tresckow, J.
    Robrecht, S.
    Giza, A.
    Zhang, C.
    Fuestenau, M.
    Dreger, P.
    Ritgen, M.
    Illmer, T.
    Illert, A. L.
    Dueig, J.
    Boettcher, S.
    Niemann, C. U.
    Kneba, M.
    Al-Sawaf, O.
    Kreuzer, K. -A
    Fink, A. -M
    Fischer, K.
    Doehner, H.
    Hallek, M.
    Eichhorst, B.
    Stilgenbauer, S.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 19 - 19
  • [42] Treatment of high-risk follicular lymphoma
    Jurczak, Wojciech
    HEMASPHERE, 2019, 3 : 85 - 87
  • [43] Treatment of high-risk cervical cancer
    Piver, MS
    NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (09): : 696 - 696
  • [44] Eflornithine for treatment of high-risk neuroblastoma
    Jiang, Jianxiong
    Yu, Ying
    TRENDS IN PHARMACOLOGICAL SCIENCES, 2024, 45 (06) : 577 - 578
  • [45] Treatment of high-risk myelodysplastic syndromes
    Kroeger, Nicolaus
    HAEMATOLOGICA, 2025, 110 (02) : 339 - 349
  • [46] Osteoporosis: treatment of high-risk patients
    Schmidmaier, Ralf
    ORTHOPADIE, 2023, 52 (10): : 799 - 807
  • [47] High-Risk Neuroblastoma Treatment Review
    Smith, Valeria
    Foster, Jennifer
    CHILDREN-BASEL, 2018, 5 (09):
  • [48] Treatment for High-Risk Smoldering Myeloma
    Dispenzieri, Angela
    Kumar, Shaji
    NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (18): : 1764 - 1764
  • [49] High-risk MCL: recognition and treatment
    Jain, Preetesh
    Wang, Michael
    BLOOD, 2025, 145 (07) : 683 - 695
  • [50] TREATMENT OF INFECTIOUS AND HIGH-RISK PATIENTS
    COWLING, RD
    BRITISH DENTAL JOURNAL, 1988, 164 (08) : 238 - 238